Skip to content

Discover Mental Health

ISSN 2731-4383

14 papers in the library · 179 citations · publishing 2022-2026

Papers

Sort Most recent Most cited

Psychedelics and neurostimulation for treatment resistant psychiatric disorders.

Discover Mental Health May 25, 2026 Filip Blazek, Klara Latalova, David Krahulik et al.

Psychedelic-assisted therapy and neurostimulation represent converging approaches to modulating dysfunctional brain circuits in treatment-resistant psychiatric disorders. This Perspective outlines shared mechanisms involving neuroplasticity and network reconfiguration, and examines ethical, regulatory, and infrastructural barriers to their translation. Bridging neuroscience, psychiatry, and...

Mindfulness-based cognitive-behavioral therapy improves sexual quality of life and reduces sexual distress in pregnant women

Discover Mental Health May 25, 2026 M. Iravani, Shahla Molavi, Saeed Ghanbari et al.

Pregnancy is accompanied by numerous physical and psychological changes that can affect sexual quality of life and increase sexual distress in women. Identifying effective interventions to address these issues is essential. This study aimed to evaluate the effect of mindfulness-based cognitive-behavioral therapy on sexual distress and sexual quality of life in pregnant women. In this...

Mindfulness-based intervention alters nonlinear heart rate variability in a pilot study.

Discover Mental Health April 11, 2026 Yu Gao, Liat Zitron, Serena Guo

Mindfulness-based interventions (MBIs) have been consistently associated with reductions in perceived stress and anxiety. One proposed mechanism underlying these effects involves a shift toward parasympathetic dominance during stress exposure, facilitating enhanced emotion regulation and physiological adaptability; however, empirical evidence on this mechanism remains inclusive. In this...

Towards social curative psychedelic treatment

Discover Mental Health March 21, 2026 Martha Newson, Leor Roseman, S. Alexander Haslam

Recent advances in psychedelic-assisted therapies highlight their efficacy in treating various mental health conditions. Nevertheless, the fact that delivery is generally individualised may limit therapeutic outcomes by failing to capitalise on opportunities to build and harness a sense of shared social identity among participants in ways hypothesised by ‘social cure’ research. In line with...

Psilocybin effects on brain functional connectivity: a systematic review of fMRI studies

Discover Mental Health March 19, 2026 Àlvar Farré-colomés, Olga Rublinetska, Oscar Soto-Angona

Psilocybin-assisted therapies are innovative therapeutic approaches, particularly in the treatment of depression. However, there are sparse studies providing functional magnetic resonance imaging (fMRI) evidence elucidating the underlying biological mechanisms that support clinical outcomes. This review aims to comprehensively gather all the evidence reported in psilocybin studies using fMRI...

The combination of exercise and psychedelics for the treatment of major depressive disorder

Discover Mental Health March 7, 2026 Nicholas Fabiano, Brendon Stubbs, David W. Lawrence et al.

Upwards of 50% of people do not respond to the primary treatment modalities for major depressive disorder (MDD), which has led to increased attention and use of alternative methods, including exercise and psychedelics. While interventions using either exercise or psychedelics have demonstrated largely positive results in isolation, their synergistic potential has yet to be explored. As such,...

Pilot study: mindfulness-based intervention reduces burnout syndrome and associated biomarkers in a Mexican university population.

Discover Mental Health January 8, 2026 Mireya Velázquez-Paniagua, Laura Gómez-Virgilio, Blanca Margarita Gómez-Chavarín et al.

INTRODUCTION: In Mexico, 25–45% of medical students experience burnout syndrome, which may be reduced through mindfulness-based interventions (MBI). No study has evaluated this intervention’s impact on our country’s population. Therefore, this study aimed to determine the effects of an eight-week MBI on medical students, professors and administrative staff from the Faculty of Medicine at the...

Social constructivist analysis of cultural concepts of distress and lycanthropy in Nagaland India

Discover Mental Health November 16, 2025 Saranya Ts, Kiniholi Yepthomi 1 citation

Abstract This systematic review examines how cultural constructs of distress and the phenomenon of lycanthropy are understood within the context of Nagaland, emphasizing a social constructivist framework. A comprehensive literature search was conducted across Google Scholar, PubMed, and PsycINFO, ultimately shortlisting 24 methodologically sound studies relevant to cultural interpretations of...

Mindfulness enhancements predict aberrant salience reductions and improve stress management.

Discover Mental Health April 8, 2025 Isabel Wießner, Júlia Paula Souza, Marcelo Demarzo et al. 3 citations

Mindfulness improves mental health and clinical conditions including psychosis and modulates attentional processes including salience-the automatic direction of attention to prominent elements. Aberrant salience-the exaggerated significance attribution to perceived elements-is associated with psychotic experiences, but its interactions with mindfulness remain unexplored. This...

Psychedelics as a potential treatment for tobacco use disorder: a systematic review.

Discover Mental Health September 17, 2024 S K Spoelstra, Robert A Schoevers, S D Venema et al. 8 citations

Despite considerable efforts, tobacco use disorder persists as a significant public health issue. The effectiveness of current smoking cessation therapies is limited, leading to a growing interest in alternative treatment approaches such as psychedelics. The aim of this review is to evaluate the scientific evidence regarding the role of psychedelics in smoking cessation. To identify relevant...

Beyond therapeutic potential: a systematic investigation of ketamine misuse in patients with depressive disorders.

Discover Mental Health July 1, 2024 Keshav Juneja, Sabah Afroze, Zeel Goti et al. 6 citations

Ketamine, a pharmacological agent that acts as an antagonist of the N-methyl-D-aspartate (NMDA) receptor, has garnered considerable interest because of its notable and expeditious antidepressant properties observed in individuals diagnosed with major depressive disorder (MDD) who exhibit resistance to conventional therapeutic interventions. A comprehensive and rigorous systematic review was...

Near-death experiences after cardiac arrest: a scoping review

Discover Mental Health May 28, 2024 Joshua G. Kovoor, Sanjana Santhosh, Brandon Stretton et al. 4 citations

Background This scoping review aimed to characterise near-death experiences in the setting of cardiac arrest, a phenomenon that is poorly understood and may have clinical consequences. Method PubMed/MEDLINE was searched to 23 July 2023 for prospective studies describing near-death experiences in cardiac arrest. PRISMA-ScR guidelines were adhered to. Qualitative and quantitative data were...

Cerebrospinal fluid metabolomes of treatment-resistant depression subtypes and ketamine response: a pilot study.

Discover Mental Health April 17, 2024 Jon Berner, Animesh Acharjee 7 citations

Depression is a disorder with variable presentation. Selecting treatments and dose-finding is, therefore, challenging and time-consuming. In addition, novel antidepressants such as ketamine have sparse optimization evidence. Insights obtained from metabolomics may improve the management of patients. The objective of this study was to determine whether compounds in the cerebrospinal fluid (CSF)...

Ketamine treatment for depression: a review

Discover Mental Health April 15, 2022 Mani Yavi, Holim Lee, Ioline D. Henter et al. 150 citations

-enantiomer, intranasal esketamine, for the treatment of major depressive disorder (MDD). Initial studies found that a single subanesthetic-dose IV ketamine infusion rapidly (within one day) improved depressive symptoms in individuals with MDD and bipolar depression, with antidepressant effects lasting three to seven days. In 2019, esketamine received FDA approval as an adjunctive treatment for...